Skip to main content
. 2011;13(4):PCC.10r01097. doi: 10.4088/PCC.10r01097

Table 6.

Medications for Acute Bipolar Depressiona

Agent Target Dose Notable Adverse Effects Notes
First-line treatments Quetiapine 300–600 mg/d Sedation, weight gain, less commonly EPS Titrate immediate-release form over 6 days
Olanzapine/fluoxetine combination Olanzapine 6–12 mg/fluoxetine 25–50 mg Sedation, weight gain, less commonly EPS
Lamotrigineb 200 mg/d Stevens-Johnson syndrome, especially with enzyme-inhibiting medications (eg, divalproex) Titrate to target dosage based on schedule appropriate for coadministered medications (see package information)
Second-line treatments Lithiumb Sufficient for blood level of 0.6–1.2 mEq/L; usual dose 900–1,800 mg Sedation, dry mouth, polyuria; more rarely kidney or thyroid failure
Divalproexb Titrate rapidly to a blood level of 85–125 μg /mL; up to 60 mg/kg Sedation, nausea, weight gain; may cause menstrual irregularities; rare pancreatitis or liver failure Very high risk of neural tube defects with fetal exposure; caution in women of childbearing age
Combinations: SSRI or bupropion with SGA, lithium, or divalproexb Antidepressants should be used only with an effective antimanic agent when treating bipolar depression Those of constituent agents While these combinations are a common practice, evidence of their efficacy is controversial
a

Based on Suppes et al,8 Malhi et al,17 Yatham et al,29 Goodwin.30

b

Not approved by the US Food and Drug Administration for this indication.

Symbol: … = no data.